Article Versions Notes

Secker K-A, Bloechl B, Keppeler H, Duerr-Stoerzer S, Schmid H, Schneidawind D, Jeong J, Hentrich T, Schulze-Hentrich JM, Schneidawind C. MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis. Cancers. 2020; 12(5):1342. https://doi.org/10.3390/cancers12051342

Secker, Kathy-Ann, Bianca Bloechl, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, Dominik Schneidawind, Johan Jeong, Thomas Hentrich, Julia M. Schulze-Hentrich, and Corina Schneidawind. 2020. "MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis" Cancers 12, no. 5: 1342. https://doi.org/10.3390/cancers12051342

Secker, K. -A., Bloechl, B., Keppeler, H., Duerr-Stoerzer, S., Schmid, H., Schneidawind, D., Jeong, J., Hentrich, T., Schulze-Hentrich, J. M., & Schneidawind, C. (2020). MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis. Cancers, 12(5), 1342. https://doi.org/10.3390/cancers12051342